Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 4:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 4,500 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer, Cancer of the Lung
Interventions
Pink and Pearl Campaign
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
5,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Lung Cancers, Gastrointestinal Cancers
Interventions
Priming Survey
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Mesothelioma, Malignant
Interventions
Placebo, Amatuximab, Pemetrexed, Cisplatin
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
La Jolla, California • Newark, Delaware • Bethesda, Maryland + 4 more
Conditions
Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
Interventions
metformin hydrochloride, placebo, Chemotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more
Conditions
Colorectal Cancer; Lung Cancer
Interventions
TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Completed Early Phase 1 Interventional Accepts healthy volunteers

Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study

NCT04267874
Conditions
Lung Carcinoma, Tobacco-Related Carcinoma
Interventions
Biospecimen Collection, Nutritional Supplementation, Placebo Administration, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
55 Years to 77 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Non-small Cell Lung Cancer
Interventions
Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Pembrolizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Lung Carcinoma, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Best Practice, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Daphne, Alabama • Hot Springs, Arkansas • Fort Myers, Florida + 17 more
Conditions
Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
Interventions
Binimetinib Pill, Hydroxychloroquine Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
PF-08098488
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Grand Rapids, Michigan • Nashville, Tennessee • San Antonio, Texas
Conditions
Non-Small Cell Lung Cancer
Interventions
Imprime PGG, MK-3475
Drug
Lead sponsor
Lawrence Feldman, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Interventions
HBI-2438
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Encinitas, California • Glendale, California • Long Beach, California + 9 more
Conditions
Lung Cancer
Interventions
Gemcitabine, Carboplatin, Paclitaxel, Radiation
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, PD-L1 Gene Mutation, Advanced Treatment-Naïve PD-L1, Sitravatinib, Pembrolizumab
Interventions
Sitravatinib, Pembrolizumab
Drug
Lead sponsor
Sarah Goldberg
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, adjuvant therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Nashville, Tennessee
Conditions
Head and Neck Cancer, Lung Cancer, Lymphoma
Interventions
Amifostine administered subcutaneously
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Miami Beach, Florida
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Chemotherapy, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
Conditions
Carcinoma, Midline
Interventions
GSK525762
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
Conditions
Thoracic Tumors, Non-small Cell Lung Cancer
Interventions
Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Bakersfield, California • Duarte, California • Los Angeles, California + 20 more
Conditions
Lung Cancer
Interventions
celecoxib, Docetaxel, pemetrexed disodium, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment
Combination Product · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Buffalo, New York